Delia-Andreea Lespezeanu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Delia-Andreea Lespezeanu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adela-Ioana Mocanu
Department of ENT&HNS, Polimed Medical Center, 040067 Bucharest, Romania
1 shared publication - Ciprian Constantin
Research Metabolism Center - Faculty of Medicine, Titu Maiorescu University 011053 Bucharest 1, 76 Al I Cuza Blvd, Romania
1 shared publication - Corina-Aurelia Zugravu
Department of Hygiene and Nutrition, “Carol Davila” University of Medicine and Pharmacy, 050463 Bucharest, Romania
1 shared publication - Cosmin Alec Moldovan
Department of Medical-Surgical and Prophylactic Disciplines, Faculty of Medicine, Titu Maiorescu University, Bucharest 031593; General Surgery Ward, ‘Witting’ Clinical Hospital, 010243 Bucharest, Romania
1 shared publication - Horia Mocanu
Department of ENT&HNS, Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania
1 shared publication Ion Pavel Antidiabetic Center
1 shared publication
Latest Publications
- Open Access
- 30 April 2025
- Published by Herald Scholarly Open Access in Food Science and Nutrition
- Vol. 11 (1) , 1-11
Preoperative Treatment of Metabolic, Vascular, and Systemic Complications Induced by the Infection with COVID-19 in Extra Digestive Cancers
Preoperative Treatment of Metabolic, Vascular, and Systemic Complications Induced by the Infection with COVID-19 in Extra Digestive Cancers
- 30 April 2025
- Published by Herald Scholarly Open Access in Food Science and Nutrition
- Vol. 11 (1) , 1-11
Open AccessPreoperative Treatment of Metabolic, Vascular, and Systemic Complications Induced by the Infection with COVID-19 in Extra Digestive Cancers
Preoperative Treatment of Metabolic, Vascular, and Systemic Complications Induced by the Infection with COVID-19 in Extra Digestive Cancers
- Open Access
- 29 July 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (15) , 1502
Perceptions of the Impact of Artificial Intelligence among Internal Medicine Physicians as a Step in Social Responsibility Implementation: A Cross-Sectional Study
Artificial Intelligence (AI) has emerged as an essential tool in healthcare for optimizing healthcare delivery and improving patient outcomes. This study is motivated by using AI in healthcare as a step for social responsibility implementation. The research aimed to investigate the attitudes of healthcare professionals on this issue, and it assessed physicians’ opinions regarding their perceptions of AI and their intention to use and implement AI tools in their activity. An electronic survey was proposed during February–June 2024 to a sample of healthcare professionals (309 were admitted into the study, 62 males and 247 females, with a mean age of 42). The results of the survey highlighted both groups’ excellent perceptions of AI and the low perceived knowledge of AI, which arises from more technical questions. The use of AI in healthcare represents a step for social responsibility implementation; it is an unstoppable process, and stakeholders should take into consideration investing more in monitoring and training activities.
- 29 July 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (15) , 1502
Open AccessPerceptions of the Impact of Artificial Intelligence among Internal Medicine Physicians as a Step in Social Responsibility Implementation: A Cross-Sectional Study
Artificial Intelligence (AI) has emerged as an essential tool in healthcare for optimizing healthcare delivery and improving patient outcomes. This study is motivated by using AI in healthcare as a step for social responsibility implementation. The research aimed to investigate the attitudes of healthcare professionals on this issue, and it assessed physicians’ opinions regarding their perceptions of AI and their intention to use and implement AI tools in their activity. An electronic survey was proposed during February–June 2024 to a sample of healthcare professionals (309 were admitted into the study, 62 males and 247 females, with a mean age of 42). The results of the survey highlighted both groups’ excellent perceptions of AI and the low perceived knowledge of AI, which arises from more technical questions. The use of AI in healthcare represents a step for social responsibility implementation; it is an unstoppable process, and stakeholders should take into consideration investing more in monitoring and training activities.
- Open Access
- 1 January 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 387-402
COVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern – Mixed-Method Systematic Review
With the advent of COVID-19, the number of patients diagnosed with mucormycosis has increased, especially in developing countries. The reason behind this increase is that COVID-19 causes hypoxia that promotes the growth of fungus. To identify the association between mucormycosis and COVID-19, in critically ill or immunocompromised COVID-19 patients. The literature included in the review was researched from October 1, 2021, to November 1, 2022, by using the Google Scholar database as the search engine. Of the 20 articles included, there were 4 case reports, 2 case series, 10 narrative reviews, and 4 quantitative studies. Mucormycetes growth is caused by several factors, including hyperglycemia owing to previously existing diabetes or excessive use of steroids, increased ferritin levels owing to the inflammatory cascade initiated by COVID-19, and immunosuppression caused by the use of steroids or other immunosuppressive therapy. Reduced white-cell count and activity in COVID-19 leads to increased germination of fungal spores hence developing a catastrophic picture of rhinocerebral mucormycosis. Considering that the hematological patient is frequently treated with cortisone, immunosuppressed due to the underlying condition, but also through the administered therapy, the association with a possible diabetes makes this patient susceptible to developing rhinocerebral mucormycosis during COVID-19 infection. Despite being severe, the association between mucormycosis and COVID-19 is specific and treatable. Development of mucormycosis in hematological patients suffering from severe COVID-19 disease is dangerous, yet not compulsory and can be prevented. Using a common steroid-dose protocol with hyperbaric oxygen and necessary preventive measure reveals the disease as a superadded infection. Hypoxia, poor glycemic control and overuse of steroids or immunosuppressive drugs cause it.
- 1 January 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 387-402
Open AccessCOVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern – Mixed-Method Systematic Review
With the advent of COVID-19, the number of patients diagnosed with mucormycosis has increased, especially in developing countries. The reason behind this increase is that COVID-19 causes hypoxia that promotes the growth of fungus. To identify the association between mucormycosis and COVID-19, in critically ill or immunocompromised COVID-19 patients. The literature included in the review was researched from October 1, 2021, to November 1, 2022, by using the Google Scholar database as the search engine. Of the 20 articles included, there were 4 case reports, 2 case series, 10 narrative reviews, and 4 quantitative studies. Mucormycetes growth is caused by several factors, including hyperglycemia owing to previously existing diabetes or excessive use of steroids, increased ferritin levels owing to the inflammatory cascade initiated by COVID-19, and immunosuppression caused by the use of steroids or other immunosuppressive therapy. Reduced white-cell count and activity in COVID-19 leads to increased germination of fungal spores hence developing a catastrophic picture of rhinocerebral mucormycosis. Considering that the hematological patient is frequently treated with cortisone, immunosuppressed due to the underlying condition, but also through the administered therapy, the association with a possible diabetes makes this patient susceptible to developing rhinocerebral mucormycosis during COVID-19 infection. Despite being severe, the association between mucormycosis and COVID-19 is specific and treatable. Development of mucormycosis in hematological patients suffering from severe COVID-19 disease is dangerous, yet not compulsory and can be prevented. Using a common steroid-dose protocol with hyperbaric oxygen and necessary preventive measure reveals the disease as a superadded infection. Hypoxia, poor glycemic control and overuse of steroids or immunosuppressive drugs cause it.